.jetcityimage/iStock Content using Getty Images Morgan Stanley has selected Eli Lilly (NYSE: LLY) as its best biopharma pick for 2025 and rated yet another 9 names in the area as over weight. The assets financial institution said in a keep in mind that it remains to feel “diabesity is set to become.